{"protocolSection": {"identificationModule": {"nctId": "NCT00554970", "orgStudyIdInfo": {"id": "MAP0010-CL-P202"}, "organization": {"fullName": "Allergan", "class": "INDUSTRY"}, "briefTitle": "A Study of 2 Doses of MAP0010 in Adult Asthmatics", "officialTitle": "A Randomized, Open Label, Active-Controlled, 4-Treatment, 2-Period, 2 Parallel Block Crossover Pharmacokinetic and Safety Study of 2 Doses of MAP0010 in Adult Asthmatics", "acronym": "P202"}, "statusModule": {"statusVerifiedDate": "2013-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-11"}, "primaryCompletionDateStruct": {"date": "2008-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-10-30", "studyFirstSubmitQcDate": "2007-11-05", "studyFirstPostDateStruct": {"date": "2007-11-07", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-08-19", "resultsFirstSubmitQcDate": "2013-08-19", "resultsFirstPostDateStruct": {"date": "2013-10-23", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-12-09", "lastUpdatePostDateStruct": {"date": "2014-01-09", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Allergan", "class": "INDUSTRY"}, "collaborators": [{"name": "MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to examine the blood levels of two doses of MAP0010 (a corticosteroid) and two doses of an approved corticosteroid in adult asthma and safety with twice daily dosing over 7 days."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Adult Asthmatics"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 32, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Treatment 1 then Treatment 2", "type": "OTHER", "description": "Subjects received Treatment 1 in period 1 followed by a 7 day washout period and then Treatment 2 in period 2. Treatment 1 was a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 2 was a single dose of Pulmicort Respules\u00ae 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol.", "interventionNames": ["Drug: MAP0010 low dose", "Drug: Budesonide inhalation suspension 0.25mg"]}, {"label": "Treatment 2 then Treatment 1", "type": "OTHER", "description": "Subjects received Treatment 2 in period 1 followed by a 7 day washout period and then Treatment 1 period 2. Treatment 1 was a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 2 was a single dose of Pulmicort Respules\u00ae 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol.", "interventionNames": ["Drug: MAP0010 low dose", "Drug: Budesonide inhalation suspension 0.25mg"]}, {"label": "Treatment 3 then Treatment 4", "type": "OTHER", "description": "Subjects received Treatment 3 in period 1 followed by a 7 day washout period and then Treatment 4 period 2. Treatment 3 was a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 4 was a single dose of Pulmicort Respules\u00ae 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol.", "interventionNames": ["Drug: MAP0010 high dose", "Drug: Budesonide inhalation suspension 0.5mg"]}, {"label": "Treatment 4 then Treatment 3", "type": "OTHER", "description": "Subjects received Treatment 4 in period 1 followed by a 7 day washout period and then Treatment 3 in period 2. Treatment 3 was a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 4 was a single dose of Pulmicort Respules\u00ae 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol.", "interventionNames": ["Drug: MAP0010 high dose", "Drug: Budesonide inhalation suspension 0.5mg"]}], "interventions": [{"type": "DRUG", "name": "MAP0010 low dose", "description": "a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol", "armGroupLabels": ["Treatment 1 then Treatment 2", "Treatment 2 then Treatment 1"]}, {"type": "DRUG", "name": "MAP0010 high dose", "description": "a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol", "armGroupLabels": ["Treatment 3 then Treatment 4", "Treatment 4 then Treatment 3"]}, {"type": "DRUG", "name": "Budesonide inhalation suspension 0.25mg", "description": "a single dose of Pulmicort Respules\u00ae 0.25mg delivered by nebulization twice daily for 7 days as per protocol", "armGroupLabels": ["Treatment 1 then Treatment 2", "Treatment 2 then Treatment 1"], "otherNames": ["Pulmicort Respules\u00ae"]}, {"type": "DRUG", "name": "Budesonide inhalation suspension 0.5mg", "description": "a single dose of Pulmicort Respules\u00ae 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol", "armGroupLabels": ["Treatment 3 then Treatment 4", "Treatment 4 then Treatment 3"], "otherNames": ["Pulmicort Respules\u00ae"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Cmax of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules\u00ae 0.25mg, and Pulmicort Respules\u00ae 0.5mg", "description": "The maximum concentration (Cmax) is the highest concentration of a drug measured in the plasma. Plasma is the clear portion of the blood. The Cmax of Budesonide is reported in picograms per milliliter (pg/ml).", "timeFrame": "Day 1 hour 12"}, {"measure": "Cmax of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules\u00ae 0.25mg, and Pulmicort Respules\u00ae 0.5mg", "description": "The maximum concentration (Cmax) is the highest concentration of a drug measured in the plasma. Plasma is the clear portion of the blood. The Cmax of Budesonide is reported in picograms per milliliter (pg/ml).", "timeFrame": "Day 8 hour 12"}, {"measure": "AUC(0-inf) of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules\u00ae 0.25mg, and Pulmicort Respules\u00ae 0.5mg", "description": "The AUC(0-inf) is the area under the plot of plasma concentration of drug against time after drug administration. Budesonide AUC(0-inf) is reported in picograms times minutes per milliliter (pg\\*min/ml).", "timeFrame": "Day 1 hour 12"}, {"measure": "AUC(0-inf) of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules\u00ae 0.25mg, and Pulmicort Respules\u00ae 0.5mg", "description": "The AUC(0-inf) is the area under the plot of plasma concentration of drug against time after drug administration. Budesonide AUC(0-inf) is reported in picograms times minutes per milliliter (pg\\*min/ml).", "timeFrame": "Day 8 hour 12"}, {"measure": "Half-life (t1/2) of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules\u00ae 0.25mg, and Pulmicort Respules\u00ae 0.5mg", "description": "Half-life (t1/2) is the time for the drug to decrease to half of its maximum concentration. Budesonide t1/2 is reported in minutes.", "timeFrame": "Day 1 hour 12"}, {"measure": "Half-life (t1/2) of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules\u00ae 0.25mg, and Pulmicort Respules\u00ae 0.5mg", "description": "Half-life (t1/2) is the time for the drug to decrease to half of its maximum concentration. Budesonide t1/2 is reported in minutes.", "timeFrame": "Day 8 hour 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female adult asthmatics with mild to moderate persistent asthma.\n* 18 to 45 (up to the 46th birthday) years of age.\n* Documented diagnosis of asthma at least 3 months prior to Visit 1, per NIH/NHLBI, EPR-3 criteria.\n* Able to withhold short-acting bronchodilators (e.g., albuterol or ipratropium bromide) for at least 4 hours prior to clinic visits.\n* Baseline FEV1 greater than or equal to 50% of predicted normal.\n\nExclusion Criteria:\n\n* Any other significant illness/abnormality\n* A history of upper or lower respiratory tract infection within 2 weeks\n* A history of acute or severe asthma attack requiring ICU admission or ventilatory support.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director", "affiliation": "MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "West Coast Clinical Trials Phase 2-4, LLC", "city": "Long Beach", "state": "California", "zip": "90806", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "National Institutes of Health", "url": "http://www.nih.gov"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "This is a 4-treatment, 2-period crossover study. Subjects were randomized to receive either Treatments 1 (MAP0010 low dose) and 2 (Pulmicort Respules\u00ae 0.25mg) or 3 (MAP0010 high dose) and 4 (Pulmicort Respules\u00ae 0.5mg). Subjects were randomized to the following sequences: Tx 1 then Tx 2, Tx 2 then Tx 1, Tx 3 then Tx 4, or Tx 4 then Tx 3", "groups": [{"id": "FG000", "title": "Treatment 1 Then Treatment 2", "description": "Subjects received Treatment 1 in period 1 followed by a 7 day washout period and then Treatment 2 in period 2. Treatment 1 was a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 2 was a single dose of Pulmicort Respules\u00ae 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol."}, {"id": "FG001", "title": "Treatment 2 Then Treatment 1", "description": "Subjects received Treatment 2 in period 1 followed by a 7 day washout period and then Treatment 1 in period 2. Treatment 1 was a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 2 was a single dose of Pulmicort Respules\u00ae 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol."}, {"id": "FG002", "title": "Treatment 3 Then Treatment 4", "description": "Subjects received Treatment 3 in period 1 followed by a 7 day washout period and then Treatment 4 in period 2. Treatment 3 was a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 4 was a single dose of Pulmicort Respules\u00ae 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol."}, {"id": "FG003", "title": "Treatment 4 Then Treatment 3", "description": "Subjects received Treatment 4 in period 1 followed by a 7 day washout period and then Treatment 3 in period 2. Treatment 3 was a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 4 was a single dose of Pulmicort Respules\u00ae 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol."}], "periods": [{"title": "Period 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "8"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "8"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Period 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "8"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "8"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Treatment 1 Then Treatment 2", "description": "Subjects received Treatment 1 in period 1 followed by a 7 day washout period and then Treatment 2 in period 2. Treatment 1 was a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 2 was a single dose of Pulmicort Respules\u00ae 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol."}, {"id": "BG001", "title": "Treatment 2, Then Treatment 1", "description": "Subjects received Treatment 2 in period 1 followed by a 7 day washout period and then Treatment 1 in period 2. Treatment 1 was a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 2 was a single dose of Pulmicort Respules\u00ae 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol."}, {"id": "BG002", "title": "Treatment 3 Then Treatment 4", "description": "Subjects received Treatment 3 in period 1 followed by a 7 day washout period and then Treatment 4 in period 2. Treatment 3 was a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 4 was a single dose of Pulmicort Respules\u00ae 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol."}, {"id": "BG003", "title": "Treatment 4 Then Treatment 3", "description": "Subjects received Treatment 4 in period 1 followed by a 7 day washout period and then Treatment 3 in period 2. Treatment 3 was a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 4 was a single dose of Pulmicort Respules\u00ae 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol."}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "8"}, {"groupId": "BG003", "value": "8"}, {"groupId": "BG004", "value": "32"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "27.4", "spread": "8.9"}, {"groupId": "BG001", "value": "30.4", "spread": "7.2"}, {"groupId": "BG002", "value": "30.0", "spread": "8.3"}, {"groupId": "BG003", "value": "29.1", "spread": "6.9"}, {"groupId": "BG004", "value": "29.2", "spread": "7.6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "7"}, {"groupId": "BG004", "value": "19"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "13"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Cmax of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules\u00ae 0.25mg, and Pulmicort Respules\u00ae 0.5mg", "description": "The maximum concentration (Cmax) is the highest concentration of a drug measured in the plasma. Plasma is the clear portion of the blood. The Cmax of Budesonide is reported in picograms per milliliter (pg/ml).", "populationDescription": "Patients with available data at specified time points are included in the analysis population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/ml", "timeFrame": "Day 1 hour 12", "groups": [{"id": "OG000", "title": "MAP0010 High Dose", "description": "a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol"}, {"id": "OG001", "title": "Pulmicort Respules\u00ae 0.50 mg", "description": "a single dose of Pulmicort Respules\u00ae 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol"}, {"id": "OG002", "title": "MAP0010 Low Dose", "description": "a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol"}, {"id": "OG003", "title": "Pulmicort Respules\u00ae 0.25 mg", "description": "a single dose of Pulmicort Respules\u00ae 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "250", "spread": "161"}, {"groupId": "OG001", "value": "365", "spread": "203"}, {"groupId": "OG002", "value": "168", "spread": "130"}, {"groupId": "OG003", "value": "197", "spread": "102"}]}]}]}, {"type": "PRIMARY", "title": "Cmax of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules\u00ae 0.25mg, and Pulmicort Respules\u00ae 0.5mg", "description": "The maximum concentration (Cmax) is the highest concentration of a drug measured in the plasma. Plasma is the clear portion of the blood. The Cmax of Budesonide is reported in picograms per milliliter (pg/ml).", "populationDescription": "Patients with available data at specified time points are included in the analysis population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/ml", "timeFrame": "Day 8 hour 12", "groups": [{"id": "OG000", "title": "MAP0010 High Dose", "description": "a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol"}, {"id": "OG001", "title": "Pulmicort Respules\u00ae 0.50 mg", "description": "a single dose of Pulmicort Respules\u00ae 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol"}, {"id": "OG002", "title": "MAP0010 Low Dose", "description": "a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol"}, {"id": "OG003", "title": "Pulmicort Respules\u00ae 0.25 mg", "description": "a single dose of Pulmicort Respules\u00ae 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "528", "spread": "257"}, {"groupId": "OG001", "value": "530", "spread": "334"}, {"groupId": "OG002", "value": "366", "spread": "262"}, {"groupId": "OG003", "value": "315", "spread": "206"}]}]}]}, {"type": "PRIMARY", "title": "AUC(0-inf) of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules\u00ae 0.25mg, and Pulmicort Respules\u00ae 0.5mg", "description": "The AUC(0-inf) is the area under the plot of plasma concentration of drug against time after drug administration. Budesonide AUC(0-inf) is reported in picograms times minutes per milliliter (pg\\*min/ml).", "populationDescription": "Patients with available data at specified time points are included in the analysis population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg*min/ml", "timeFrame": "Day 1 hour 12", "groups": [{"id": "OG000", "title": "MAP0010 High Dose", "description": "a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol"}, {"id": "OG001", "title": "Pulmicort Respules\u00ae 0.50 mg", "description": "a single dose of Pulmicort Respules\u00ae 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol"}, {"id": "OG002", "title": "MAP0010 Low Dose", "description": "a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol"}, {"id": "OG003", "title": "Pulmicort Respules\u00ae 0.25 mg", "description": "a single dose of Pulmicort Respules\u00ae 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "19400", "spread": "7280"}, {"groupId": "OG001", "value": "55900", "spread": "19800"}, {"groupId": "OG002", "value": "10300", "spread": "4620"}, {"groupId": "OG003", "value": "26900", "spread": "7420"}]}]}]}, {"type": "PRIMARY", "title": "AUC(0-inf) of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules\u00ae 0.25mg, and Pulmicort Respules\u00ae 0.5mg", "description": "The AUC(0-inf) is the area under the plot of plasma concentration of drug against time after drug administration. Budesonide AUC(0-inf) is reported in picograms times minutes per milliliter (pg\\*min/ml).", "populationDescription": "Patients with available data at specified time points are included in the analysis population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg*min/ml", "timeFrame": "Day 8 hour 12", "groups": [{"id": "OG000", "title": "MAP0010 High Dose", "description": "a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol"}, {"id": "OG001", "title": "Pulmicort Respules\u00ae 0.50 mg", "description": "a single dose of Pulmicort Respules\u00ae 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol"}, {"id": "OG002", "title": "MAP0010 Low Dose", "description": "a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol"}, {"id": "OG003", "title": "Pulmicort Respules\u00ae 0.25 mg", "description": "a single dose of Pulmicort Respules\u00ae 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "58700", "spread": "25700"}, {"groupId": "OG001", "value": "90100", "spread": "38200"}, {"groupId": "OG002", "value": "35500", "spread": "15000"}, {"groupId": "OG003", "value": "45200", "spread": "19500"}]}]}]}, {"type": "PRIMARY", "title": "Half-life (t1/2) of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules\u00ae 0.25mg, and Pulmicort Respules\u00ae 0.5mg", "description": "Half-life (t1/2) is the time for the drug to decrease to half of its maximum concentration. Budesonide t1/2 is reported in minutes.", "populationDescription": "Patients with available data at specified time points are included in the analysis population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "min", "timeFrame": "Day 1 hour 12", "groups": [{"id": "OG000", "title": "MAP0010 High Dose", "description": "a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol"}, {"id": "OG001", "title": "Pulmicort Respules\u00ae 0.50 mg", "description": "a single dose of Pulmicort Respules\u00ae 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol"}, {"id": "OG002", "title": "MAP0010 Low Dose", "description": "a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol"}, {"id": "OG003", "title": "Pulmicort Respules\u00ae 0.25 mg", "description": "a single dose of Pulmicort Respules\u00ae 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "168", "spread": "95.7"}, {"groupId": "OG001", "value": "207", "spread": "110"}, {"groupId": "OG002", "value": "112", "spread": "49.0"}, {"groupId": "OG003", "value": "179", "spread": "75.8"}]}]}]}, {"type": "PRIMARY", "title": "Half-life (t1/2) of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules\u00ae 0.25mg, and Pulmicort Respules\u00ae 0.5mg", "description": "Half-life (t1/2) is the time for the drug to decrease to half of its maximum concentration. Budesonide t1/2 is reported in minutes.", "populationDescription": "Patients with available data at specified time points are included in the analysis population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "min", "timeFrame": "Day 8 hour 12", "groups": [{"id": "OG000", "title": "MAP0010 High Dose", "description": "a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol"}, {"id": "OG001", "title": "Pulmicort Respules\u00ae 0.50 mg", "description": "a single dose of Pulmicort Respules\u00ae 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol"}, {"id": "OG002", "title": "MAP0010 Low Dose", "description": "a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol"}, {"id": "OG003", "title": "Pulmicort Respules\u00ae 0.25 mg", "description": "a single dose of Pulmicort Respules\u00ae 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "193", "spread": "67.2"}, {"groupId": "OG001", "value": "192", "spread": "66.3"}, {"groupId": "OG002", "value": "248", "spread": "192"}, {"groupId": "OG003", "value": "230", "spread": "130"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "description": "Adverse events are presented by treatment arm, not by individual treatment (intervention) received.", "eventGroups": [{"id": "EG000", "title": "Treatment 1 Then Treatment 2", "description": "Subjects received Treatment 1 in period 1 followed by a 7 day washout period and then Treatment 2 in period 2. Treatment 1 was a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 2 was a single dose of Pulmicort Respules\u00ae 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol.", "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 7, "otherNumAtRisk": 8}, {"id": "EG001", "title": "Treatment 2, Then Treatment 1", "description": "Subjects received Treatment 2 in period 1 followed by a 7 day washout period and then Treatment 1 in period 2. Treatment 1 was a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 2 was a single dose of Pulmicort Respules\u00ae 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol.", "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 2, "otherNumAtRisk": 8}, {"id": "EG002", "title": "Treatment 3 Then Treatment 4", "description": "Subjects received Treatment 3 in period 1 followed by a 7 day washout period and then Treatment 4 in period 2. Treatment 3 was a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 4 was a single dose of Pulmicort Respules\u00ae 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol.", "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 3, "otherNumAtRisk": 8}, {"id": "EG003", "title": "Treatment 4 Then Treatment 3", "description": "Subjects received Treatment 4 in period 1 followed by a 7 day washout period and then Treatment 3 in period 2. Treatment 3 was a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 4 was a single dose of Pulmicort Respules\u00ae 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol.", "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 3, "otherNumAtRisk": 8}], "otherEvents": [{"term": "Iron deficiency anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Malaise", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Skin infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}]}, {"term": "Nasal congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}]}, {"term": "Nasal polyps", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Throat irritation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo."}, "pointOfContact": {"title": "VP, Scientific Affairs", "organization": "MAP Pharmaceuticals Inc., a wholly owned subsidiary of Allergan", "email": "dkellerman@mappharma.com", "phone": "650-386-3100"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthmatic", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019819", "term": "Budesonide"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}], "browseLeaves": [{"id": "M21711", "name": "Budesonide", "asFound": "Of 1", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}